Pharmaceutical Technology, Sep 1, 2012 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Pharmaceutical Technology, Sep 1, 2012
Articles
Strategies for High-Containment
By Patricia Van Arnum
An industry roundtable representing Metrics, Cambrex, Carbogen Amcis, Euticals, Ferro Pfanstiehl, and SAFC.
Making API Synthesis Greener
By Tom Moody , Gareth Brown
The authors explain chemical transformations that are achievable through certain biocatalytic routes.
Plant Focus: High-Potency Manufacturing and Sustainability at Pfizer
By Patricia Van Arnum
Pfizer has two manufacturing facilities in Germany for high-potency manufacturing, respectively in Freiburg and Illertissen. Pharmaceutical Technology's Executive Editor Patricia Van Arnum visited the facilities and spoke to the company about the design and operation of these facilities.
Developing the Optimal Solid Form
By David Igo , Stephen Carino
The authors describe a solid form technology platform used to optimize salt selection, cocrystallization identification and modification, or the development of a free form.
Achieving Process Understanding and Control in Film Coating
By Eric Van Ness , Beverly Schad , Thomas Riley , Brian Cheng
The authors describe a QbD study that was performed to optimize a coating system.
Excipients in Tastemasking
By Patricia Van Arnum
A Q&A with BASF moderated by Patricia Van Arnum.
The Project Management of Project Management
By Trish Melton
This article presents an overview of ISPE's guide on project management.
Moving to Risk-Based Inspections
By Patricia Van Arnum
The author discusses the key provisions of GDUFA as they relate to the pharmaceutical supply chain, including parity of inspections between domestic and foreign sites for both finished dosage forms and APIs of generic drugs.
Weighing Access and Affordability
By Kenneth I. Kaitin , Joshua P. Cohen
Policymakers must balance fundamental issues involving access to medicines and pricing.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here